S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
CNSX:LXX

Lexaria Bioscience Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume48,200 shs
Average Volume250,001 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive LXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.


About Lexaria Bioscience

Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Lexaria Bioscience (CNSX:LXX) Frequently Asked Questions

What stocks does MarketBeat like better than Lexaria Bioscience?

Wall Street analysts have given Lexaria Bioscience a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexaria Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Lexaria Bioscience's key executives?

Lexaria Bioscience's management team includes the following people:
  • Mr. Christopher A. Bunka, Chairman & CEO (Age 57)
  • Mr. John M. Docherty, Pres & Director (Age 50)
  • Mr. Allan Spissinger, CFO, Corp. Sec. & Treasurer (Age 50)
  • Mr. Alex Blanchard, Mang. Corp. Communications & Investor Relations
  • Dr. Edward Ergenzinger, Chief Legal Officer & Sr. VP of Innovation

What other stocks do shareholders of Lexaria Bioscience own?

What is Lexaria Bioscience's stock symbol?

Lexaria Bioscience trades on the CNSX under the ticker symbol "LXX."

How do I buy shares of Lexaria Bioscience?

Shares of LXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexaria Bioscience's official website?

The official website for Lexaria Bioscience is www.lexariaenergy.com.

How can I contact Lexaria Bioscience?

The company can be reached via phone at 250-765-6424.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.